Citigroup
CMPX icon

Citigroup’s Compass Therapeutics CMPX Stock Holding History

Citigroup’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.16M Buy
598,238
+336,362
+128% +$1.94M ﹤0.01% 2325
2025
Q4 		$1.41M Buy
261,876
+251,225
+2,359% +$1.16M ﹤0.01% 2903
2025
Q3 		$37.3K Sell
10,651
-21,059
-66% -$66.5K ﹤0.01% 4583
2025
Q2 		$82.4K Sell
31,710
-99,527
-76% -$205K ﹤0.01% 4504
2025
Q1 		$249K Buy
131,237
+52,634
+67% +$140K ﹤0.01% 4068
2024
Q4 		$114K Buy
78,603
+4,322
+6% +$7.18K ﹤0.01% 4766
2024
Q3 		$137K Buy
74,281
+51,150
+221% +$63.8K ﹤0.01% 4611
2024
Q2 		$23.1K Buy
23,131
+6,089
+36% +$8.89K ﹤0.01% 4962
2024
Q1 		$33.7K Buy
17,042
+3,640
+27% +$6.29K ﹤0.01% 4830
2023
Q4 		$20.9K Buy
13,402
+13,219
+7,223% +$22.9K ﹤0.01% 4973
2023
Q3 		$361 Sell
183
-28,905
-99% -$71.5K ﹤0.01% 5250
2023
Q2 		$92.5K Sell
29,088
-113,853
-80% -$357K ﹤0.01% 4287
2023
Q1 		$467K Buy
142,941
+16,626
+13% +$65.3K ﹤0.01% 3171
2022
Q4 		$635K Buy
126,315
+121,782
+2,687% +$486K ﹤0.01% 2993
2022
Q3 		$10K Buy
4,533
+3,163
+231% +$8.76K ﹤0.01% 4980
2022
Q2 		$4K Buy
+1,370
New +$2.97K ﹤0.01% 5666
2022
Q1 		– Sell
-37,834
Closed -$120K – 6338
2021
Q4 		$120K Buy
+37,834
New +$125K ﹤0.01% 4638

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's CMPX Position: Q1 2026 in Review

Citigroup increased its Compass Therapeutics (CMPX) stake by 128% in Q1 2026, buying an estimated $1.94M and bringing the position to 598,238 shares worth $3.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Citigroup first reported a position in CMPX in Q4 2021 and has held it in 17 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Citigroup held 598,238 shares of Compass Therapeutics worth $3.16M as of Q1 2026.
  • Citigroup bought 336,362 Compass Therapeutics shares in Q1 2026, an estimated $1.94M.
  • Compass Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2325 holding.
  • Citigroup first reported a position in Compass Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.